Skip to main content

FDA Approves More Broadly Protective Meningococcal Vaccine, Penmenvy

By Stephanie Brown HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 19, 2025.

via HealthDay

TUESDAY, Feb. 18, 2025 -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), according to a press release from GlaxoSmithKline (GSK).

Penmenvy, approved for use in individuals aged 10 through 25 years, targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), the common cause of IMD. The vaccine is an injectable suspension for intramuscular use that combines components of GSK's two well-established meningococcal vaccines, Bexsero and Menveo.

The vaccine's safety, tolerability, and immune response were supported by two phase 3 trials with more than 4,800 participants aged 10 to 25 years. The safety profile was found to be consistent with GSK's licensed meningococcal vaccines. The most common side effects reported were pain at the injection site, fatigue, headache, muscle pain, and nausea.

"The consequences of IMD can be devastating for those who contract it, for their families and friends," Judy Klein, president and founder of Unity Consortium, a nonprofit organization focused on adolescent health and immunization in the United States, said in a statement. "We welcome new tools to help protect more adolescents from meningococcal disease. Pentavalent MenABCWY vaccines could help address the disease by providing protection against the five vaccine-preventable serogroups in one vaccine and making it easier for adolescents to get the coverage they need."

Approval of Penmenvy was granted to GSK.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

CDC Vaccine Expert Resigns After RFK Jr. Cuts Advisers

WEDNESDAY, June 18, 2025 — A senior scientist at the U.S. Centers for Disease Control and Prevention (CDC) has resigned, warning that changes in leadership may weaken the...

COVID Vaccine Protects Against Kidney Damage During Infection

MONDAY, June 16, 2025 — Kidney damage is common during a severe case of COVID-19, but vaccination appears to protect people against this life-threatening side effect, a new...

RFK Jr. Installs Critics on Vaccine Recommendation Panel

THURSDAY, June 12, 2025 — Days after ousting all 17 members of the panel that makes U.S. vaccine recommendations, Health Secretary Robert F. Kennedy Jr. has begun remaking...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.